Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06930794 | A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive(KUNPENG-3) | recruiting | Phase 3 | 300 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561567 | Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device(E20241186) | recruiting | — | 50 | Tianjin Medical University Cancer Institute and Hospital |
| 1 |
| May 1, 2026 |
| clinicaltrials |
| NCT07563205 | Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer(OMAE) | recruiting | — | 100 | GFPC InvestigationOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05191485 | Shared Decision Making in Patients With Lung Cancer | recruiting | — | 190 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05398094 | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy(MERIT-lung) | recruiting | Phase 2 | 19 | Fundación GECPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07279402 | TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% | recruiting | — | 150 | Antalya Training and Research HospitalOTHER_GOV | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07309952 | Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC(SACTION 2501) | recruiting | Phase 2 | 28 | Yang HongOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05122806 | Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC(BIOEXALK) | recruiting | N/A | 100 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06247826 | Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion(RESAMEX) | recruiting | N/A | 30 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06620835 | Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib(OPTALK) | recruiting | Phase 2 | 45 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies(PROMETHEE) | recruiting | Phase 4 | 500 | GFPC InvestigationOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05168566 | Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 99 | Teligene USINDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT05528458 | Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma | recruiting | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer(USZ-STRIKE) | recruiting | Phase 3 | 180 | ETOP IBCSG Partners FoundationNETWORK | 5 | Apr 27, 2026 | clinicaltrials |
| NCT07243132 | Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)(LUNGEVITY) | recruiting | — | 1,000 | GFPC InvestigationOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06010329 | A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | recruiting | Phase 2 | 66 | Teligene USINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06687408 | Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques | recruiting | — | 450 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT07548060 | A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy(TROP-LUNG) | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06623656 | Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | recruiting | Phase 2 | 112 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05482568 | A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 324 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence(GASTIVA) | recruiting | Phase 4 | 5,384 | Samsung Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06838273 | A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) | recruiting | Phase 3 | 720 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07276789 | Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer | recruiting | Phase 2 | 35 | Integro TheranosticsINDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07323641 | Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538947 | Real-Time Imaging to Improve Lung Cancer Diagnosis : Comparing Confocal Laser Endomicroscopy (CLE) With Standard Biopsy for Quicker and Safer Detection of Non-Small Cell Lung Cancer(SCORACLE) | recruiting | — | 70 | Central Hospital, Nancy, FranceOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07535463 | A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02468024 | JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer(STABLE-MATES) | recruiting | Phase 3 | 272 | University of Texas Southwestern Medical CenterOTHER | 4 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03948100 | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers | recruiting | N/A | 400 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06688422 | Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy(INSPIRE-CRT) | recruiting | N/A | 100 | The Cooper Health SystemOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07020065 | Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | recruiting | Phase 2 | 156 | Swiss Cancer InstituteOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07288034 | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial | recruiting | Phase 2 | 535 | City of Hope Medical CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06141070 | Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease(ANDROMEDA) | recruiting | Phase 3 | 240 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06992739 | Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)(PROTECT-2) | recruiting | Phase 2 | 49 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07528274 | Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529145 | Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment | recruiting | — | 90 | Medical University of BialystokOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT04937283 | Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | N/A | 690 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 194 | Nuvation Bio Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06660407 | Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06865339 | Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer(TRIPL) | recruiting | Phase 2 | 76 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07195084 | To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer(HyPROS-LC) | recruiting | N/A | 12 | Anhui Provincial Cancer HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05445791 | Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations(METLUNG) | recruiting | Phase 3 | 312 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2026source: clinicaltrials